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Abstract
The burden of hepatocellular carcinoma (HCC), the most common form of liver cancer, is steadily growing because obesity, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD) are replacing viral- and alcohol-related liver disease as major pathogenic promoters. The most worrisome aspects of these new risk factors are their large spread in the general population and
their link with HCC arising in noncirrhotic livers. HCC may be the presenting feature of an asymptomatic nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD. The HCC risk connected to metabolic factors has been underestimated so far, and a poorer surveillance has prevented an adequate treatment. Systemic and hepatic molecular mechanisms involved in obesity- and NAFLD-induced hepatocarcinogenesis as well as potential early markers of HCC are being extensively investigated. This review summarizes current evidence linking obesity,NAFLD and liver cancer, discusses its clinical impact and describes the main mechanisms underlying this complex relationship.

INTRODUCTION
The prevalence of obesity has reached epidemic proportions, with a steep increase in recent
decades. Besides elicitingmetabolic and cardiovascular disorders, obesity is also an established risk
factor for several types of cancer, predominantly in the gastrointestinal tract, where the strongest
associations are with pancreatic and liver cancer (1). Primary liver cancer is the fifthmost common
malignancy worldwide, and it has a yearly fatality ratio of approximately 1, indicating that most
cases do not survive a year.Hepatocellular carcinoma (HCC) accounts for 70–85% of the total liver
cancer burden and usually develops within a background of advanced chronic liver disease, mainly
related to hepatitis B virus (HBV), hepatitis C virus (HCV), and alcohol abuse. HCC is increasing
in the United States and in other countries, with an age-adjusted incidence rising from 1.5 to
4.9 per 100,000 individuals in the past 30 years (2). Although half of this increase is attributed to
long-term HCV exposure between 1960 and 1970, approximately 15–50% of HCC cases remain
idiopathic; however, recent studies identified nonalcoholic fatty liver disease (NAFLD) as the
underlying cause in 13–38.2% of patients presenting with HCC unrelated to virus and alcohol
(3).
The term NAFLD was coined by gastroenterologists almost 20 years ago to define a spectrum
of progressive liver disease that encompasses simple steatosis, nonalcoholic steatohepatitis
(NASH—histologically characterized by steatosis, necroinflammation, and/or fibrosis) and, ultimately,
cirrhosis. NAFLD is tightly associated with the metabolic syndrome (MetS) and affects
up to one-third of the general population, whereas NASH is diagnosed in 5–7% of individuals (4).
These percentages considerably increase in the high-risk groups of obese and diabetics. Although
estimates vary, one large European study found NAFLD in 94% of obese patients [body mass
index (BMI) >30 kg/m2], including 25% with NASH, and an overall prevalence of NAFLD in
patients with type 2 diabetes mellitus (T2DM) ranging from 40% to 70% (5). NAFLD currently
represents themost common liver disease inWestern countries, with a burden ofNAFLD-related
cirrhosis about twice as high as that caused by chronic hepatitis C, and is projected to be the principal
reason for liver transplantation (LT) within the decade (6). Although cirrhosis is a major
risk factor for liver cancer in humans, a growing burden of evidence demonstrates that HCC can
develop in individuals with NAFLD who do not have cirrhosis (7). The aim of this review is to
detangle the complicated relationship between liver cancer, obesity, and NAFLD and to describe
its clinical impact.

HEPATOCELLULAR CARCINOMA AND OBESITY

Obesity makes a large contribution to overall HCC burden, either alone or as cofactor, as highlighted by several large-scale epidemiological studies (1, 8–12) (Table 1).
In a cohort of 900,000 American adults, the risk of dying from liver cancer was 4.5 times
higher in men with a BMI of 35 kg/m2 or above compared to the group with a normal BMI
(18.5–25 kg/m2) (1). In a longitudinal cohort study including 578,700 subjects, obesity and MetS
predicted the development of HCC over the 12-year observation period, with a relative risk (RR)
of 1.39 and 1.35, respectively (13). Besides BMI itself, weight gain in adulthood increases the
risk for HCC by up to 2.5-fold (14). A recent meta-analysis including more than seven million
participants concluded that the summary RR of liver cancer was 17% for overweight subjects and
89% for the obese, with an average 24% increase in risk for each 5 kg/m2 increase in BMI (15).
In this setting, the importance of the pattern of fat accumulation has been addressed by only few
studies. In the EPIC (European Prospective Investigation into Cancer) cohort, the waist-to-hip
ratio (WHR), a rough estimate of abdominal fat, predicted better than BMI the incidence ofHCC
over an 8.6-year follow-up and conferred a threefold HCC risk to subjects in the upper tertile of 
WHR(14).Given this intriguing preliminary evidence, the role of visceral rather than generalized
adiposity in HCC risk certainly deserves ad hoc studies.
Overweight and obesity are also well-known cofactors for HCC development in patients with
viral or alcohol-related chronic liver disease, although their importance is often underestimated.
In a Taiwanese population study, obesity was associated with a twofold risk of HCC in patients
without viral infections but with a fourfold risk in anti-HCV-positive subjects. A synergistic effect
has been observed: when both obesity and diabetes are present, the risk of HCC in HBV or HCV
carriers can increase more than 100-fold, indicating that screening for metabolic conditions in
subjects with chronic viral liver disease is not trivial (16).
The contribution of T2DM to the overall risk of HCC seems to be independent of obesity
(Table 1). In a large cohort study, the risk of malignancy was 20% higher in patients with T2DM
than in those without and was mostly due to the development of HCC (17), with a hazard ratio
(HR) of 2.24 in males and 1.94 in females. Similar conclusions were drawn in a case-control series
(18), where T2DM was twice as prevalent in HCC patients as in controls (43% versus 19%) and
increased threefold the risk for HCC. In a longitudinal study (19) on a large cohort of patients with
or without T2DM (173,643 and 650,620 subjects respectively), after 10–15 years the incidence of
HCC was twofold higher in diabetics (2.39 versus 0.87 per 10,000 person-years, respectively), and
was proportional to follow-up duration (RR was 1.55 for patients who had <5 years of follow-up,
1.50 for those with 5–10 years, and 2.03 for those with >10 years). Although further evaluation
is required to draw definite conclusions, it is estimated that T2DM can increase the risk of HCC
by roughly two- to threefold, and the development of HCC is the most worrisome liver-related




HEPATOCELLULAR CARCINOMA AND NONALCOHOLIC FATTY LIVER DISEASE

Both obesity and T2DM per se exert a carcinogenic potential, but the underlying presence of
NAFLD and NASH is usually underestimated, and HCC may be the presenting feature of a
clinically insidious and asymptomatic liver disease. The evidence that the development of HCC is
part of the natural history of NAFLD derives from heterogeneous studies performed in subjects
with a clinical diagnosis of NAFLD, with biopsy-proven evidence of NASH, or with NASHrelated
cirrhosis or cryptogenic cirrhosis (Table 2).

HCC in NAFLD-Related Cirrhosis

The first report onHCC complicatingNAFLD with cirrhosis was published in the 1990s. Further
studies indicated that although steatosis has an almost negligible effect on liver-related mortality,
NASH is a risk factor for the development of cirrhosis and HCC (23). 
The exact burden of HCC related to NAFLD remains uncertain, but NAFLD was the most
common underlying etiologic risk factor for HCC (59%) in a US population–based study, with a
cumulative incidence of 0.3% over a 6-year follow-up (24). The mortality rates for HCC ranged
from 0.25% to 2.3% over 8.3 and 13.7 years of follow-up in two further studies (25, 26) and were up to 3–6% over 21 years in a third one. As expected, the risk of HCC was more elevated in NAFLD patients with advanced liver disease. In the largest prospective community-based study performed so far (27), after a mean follow-up of 7.6 years, only 0.5% of patients developed HCC but the rate among cirrhotics was 10%. Two longitudinal studies on the natural history of NASH-related cirrhosis in the United States (28) and Japan (27) confirmed that HCC was the cause of 47%
of deaths in NASH patients, representing an independent risk factor for liver-related mortality
(HR 7.96).
Overall, the relative HCC risk and mortality rate in NASH-related cirrhosis seem to be lower
than in viral or alcohol-related cirrhosis. In a large cohort study, HCC was significantly more
common inHCV than in NAFLD (6.8% versus 2.4%, respectively) (29), and theHCV cohort had
an approximate 0.15% risk per year ofHCCdevelopment versus 0.05% in NAFLD. However, the
common perception that HCC is a rare and late complication of NAFLD has been challenged by
recent reports that definitely unveiledwhatwe are going to face in the next decades. In northeastern
England, the overall incidence of HCC rose 1.8-fold from 2000 to 2010, but most shocking was
a more-than-tenfold increase in HCC associated with NAFLD, accounting for 34.8% of all the
cases in 2010 and making it the single most common underlying etiology (30). Not surprisingly,
this rising incidence of HCC was associated with an increasing prevalence of overweight and
obesity (61% in 2000 and 65.5% in 2010).
It is necessary to recall that NAFLD may remain unrecognized in cases of HCC arising in
cryptogenic cirrhosis, a condition for which no underlying etiology has been clinically identified.
It is estimated that 20–40% of all HCC cases in industrialized countries occur in patients with
cryptogenic cirrhosis. Most of the cases have been identified as “burnout NASH,” bearing historical
or metabolic vestiges of MetS but no longer having classic biopsy features (31, 32), which
often disappear in cirrhosis.
In order to foresee the future trends of HCC in the general population, we need to understand
that the lower rates of incidence ofHCC arising inNAFLD cirrhosis compared with other causes
of chronic liver disease are definitely outweighed by the much larger spread of NAFLD in the
general population and by the onset of HCC in noncirrhotic livers.

HCC in Noncirrhotic Liver with NAFLD

The most worrisome issue highlighted by a rapidly growing literature is the onset of HCC in
NASH patients who do not have cirrhosis yet. Since 2004, at least 116 such cases have been
reported. A French study analyzed a cohort of 31 HCC patients with MetS as the only risk factor
for liver disease and found mild or no fibrosis in most cases, compared to those harboring HCC
associated with an overt cause of liver disease (65% versus 26%, p < 0.0001) (33). HCC cases
arising in the context of MetS were more likely to be well differentiated (28% versus 64.5%), and
one-third of these cases developed in a preexisting liver cell adenoma (33). These data concur
well with larger Japanese studies, where cirrhosis was absent in 38% of 292 (34) and 49% of 87
patients (35) with NAFLD-related HCC, and with an English epidemiological study, where the
same observation was made in one-third of the NAFLD cases (30). As these patients were not
in surveillance programs, the majority (62.3%) presented symptomatically, with larger tumors,
and their median survival was just 7.2 months. Hence, the number of individuals with NAFLD
potentially at risk for developingHCCmay bemuch larger than previously thought. This reveals an
urgent need to better understand the risk factors linked to the development ofHCCin noncirrhotic
livers and to update screening programs.

MOLECULAR MECHANISMS OF HEPATOCARCINOGENESIS

Mechanisms of HCC arising in long-standing cirrhosis have been extensively described (40) and
are generally characterized by recurrent cycles of hepatocellular death and compensatory regeneration, accompanied by constant cell growth and proliferation that favor tumor development.
However, the mechanisms relating obesity, NAFLD, and HCC, particularly in the absence of
cirrhosis, are probably related to the pathogenesis of the underlying disease rather than to fibrosis
alone and are still unclear (40). The common soil of insulin resistance (IR) and hepatic steatosis
favors liver carcinogenesis by promoting adipose tissue–derived inflammation (41), hormonal
changes (42), oxidative stress and lipotoxicity (43–45), and stimulation of the IGF-1 axis by hyperinsulinemia (46). Others mechanisms involving diet (47, 48), gut microbiome (49, 50) and
genetic factors are increasingly important and clinically relevant (51) (Figure 1).

Dysfunctional Adipose Tissue and Proinflammatory Cytokine Pathways

The low-grade chronic inflammation characteristic of IR, particularly in the setting of obesity,
favors macrophage recruitment and massive release of several proinflammatory cytokines (52).
Among these, tumor necrosis factor alpha (TNFα) and interleukin (IL)-6 have been more clearly
linked to the progression from NASH to HCC (41), mainly through their action on the IKK
and JNK signaling pathways, which are the pivotal mediators of obesity-induced inflammation
and are also involved in liver tumorigenesis. TNFα can induce activation of JNK, leading to
impairment of the normal insulin receptor signaling (53), and interacts with NF-κB to promote
the transcription of genes involved in apoptosis, inflammation, proliferation, and angiogenesis.
IL-6 is able to activate STAT3, which promotes cell growth and differentiation (54). The higher
IL-6 levels in obese subjects and the involvement of STAT3 in different cancers indirectly suggest
a role of this pathway in HCC development.
High leptin and low adiponectin levels are two hallmarks of obesity and are both involved in
NAFLD progression and carcinogenesis. Leptin contributes to the development of IR, hepatic
steatosis, and fibrosis, and plays an important role in the regulation of immune response, glucose
homeostasis, and angiogenesis (55). Leptin binding to the Ob receptor leads to the activation of
different molecular pathways, such as JAK 2/STAT3 and PI-3K/Akt. One of the most important
downstream effectors of Akt is mTOR, a serine-threonine protein kinase implicated in cell growth,
proliferation, and survival (56). The activation of the Akt/mTOR pathway has been reported in
about 30–40% of HCC patients and can be negatively regulated by PTEN (56). Liver PTENdeficient mice develop steatosis, inflammation, fibrosis, and HCC similar to human NASH.
Conversely, adiponectin is able to reduce STAT3 and Akt phosphorylation in vitro by upregulating
the expression of SOCS3 (57), but in the setting of IR and obesity, low levels of adiponectin
hamper its anti-inflammatory activity and its antagonizing effect on leptin-induced hepatocellular
carcinogenesis.

Diet and Gut Microbiome

The composition of diet can significantly influence the above-described pathways. IL-6 andTNFα
expression in the liver is strongly induced in response to a high-fat diet, which can also increase
NF-κB activation (40). A high carbohydrate intake can activate the transcription factor ChREBP
and acts in concert with chronic hyperinsulinemia, through SREBP-1c, to induce hepatic lipogenic
gene expression. De novo lipogenesis is upregulated by threefold in obese, diabetic, and
NAFLD subjects and produces exclusively saturated fatty acids, which amplify lipotoxic injury
(58). Fructose, in particular, seems to favor HCC initiation through a cascade of different events:
It increases lipoperoxidation by stimulating de novo lipogenesis and blocking the conversion of
free fatty acids (FFAs) into triglycerides for hepatic ATP depletion (59); it downregulates the
expression of sirtuin-1, which is involved in the regulation of cellular survival; and finally, it alters
the intestinal microbiome composition (60). Changes in composition of the gut microbiota are
tightly associated with obesity and contribute to hepatic inflammation through increased intestinal
permeability, translocation of bacterial components such as lipopolysaccharides, and activation of
the toll-like receptors. Notably, deoxycholic acid, a secondary bile acid produced mainly by the
gram-positive bacteria Clostridium, can produce reactive oxygen species leading to DNA damage
and release of SASP from hepatic stellate cells (HSCs) (51). This HSC molecular signature has
been described also in the absence of severe fibrosis, thus helping to unveil the obscure mechanisms




In the past eight years, genome-wide association studies (GWAS)led to the identification of several
genes related to NAFLD, NASH, and its complications including HCC. In 2008, Romeo et al.
(61) described a single-nucleotide polymorphism (SNP) in the patatin-like phospholipase domaincontaining 3 (PNPLA3) gene, which encodes the triglyceride lipase adiponutrin and strongly affects fat accumulation in the liver in the absence of IR. The PNPLA3 rs738409 [G] risk allele, found in ∼40% of the European population, can also increase threefold the risk of progression to NASH and, most importantly, twelve-fold that of developing HCC (62). Among HCC patients, GG
homozygosity is also associated with younger age, shorter history of cirrhosis or less advanced liver
disease, and more diffuse HCC at diagnosis, hence reduced survival. A meta-analysis including
2,503 European cirrhotic patients found that the rs738409[G] allele was strongly associated with
overallHCCindependent of obesity, particularly in alcohol-related cirrhosis (63).The relationship
between this mutation and liver damage or HCC onset remains to be established, but rs738409
has been linked to increasing circulating levels of ICAM-1 and decreased levels of adiponectin.
Finally, uncommon genetic variants seem to influence HCC development in a fatty liver. The
most important are the nonsense mutation c.6718A>T in the apolipoprotein B (ApoB) gene,
identified through whole-exome sequencing in a family with hypobetalipoproteinemia, and the
human telomerase reverse transcriptase (TERT ) gene, which is upregulated in human cancer and
is a hallmark of HCC in patients carrying loss-of-function TERT mutations (51). Although only
a few SNPs have been associated with the development of HCC, they are clinically relevant for
potential use as markers of HCC in NAFLD.

HEPATOCELLULAR CARCINOMA SURVEILLANCE AND PREVENTION

Poor surveillance is a constant problem forNAFLDpatients. Their risk ofHCCis often underestimated,
and the disease is often asymptomatic for decades and associated with several comorbidities.
In one of the most recent studies, 46.2% of patients with HCV-related HCC, 32.0% of patients
with alcohol-related HCC, and just 22.8% of patients with NAFLD had their HCC detected by
surveillance (64). The onset of HCC in noncirrhotic NASH has resulted in further uncertainty
about the optimal screening strategy for the early detection of HCC, essential for curative therapies.
Generalized HCC screening programs adopted in cirrhotic patients (abdominal ultrasound
every six months) (68) would not be cost effective because of the high prevalence of NAFLD in
the general population (26). Three out of five guidelines on the management of NAFLD support
the practice of oncologic follow-up on an individual basis, particularly for patients with obesity
and T2DM; the guidelines of the Asia-Pacific region suggest the extension of screening to those
“cancers whose incidence is increased by MetS,” but specific recommendations in noncirrhotic
patients are currently lacking. It is conceivable that the development of polymorphism-based risk
scoring algorithms will enable the identification of high-risk groups for HCC.
The use of metformin has been recently linked to antineoplastic effects through both insulin dependent and -independent mechanisms (65). A meta-analysis including 22,650 cases of HCC
in 334,307 patients with T2DM concluded that incidence of HCC was reduced by 50% with
metformin use, increased with sulfonylurea or insulin and unchanged with glitazones (66).
Statinsmay also decrease the risk of cancers through antiproliferative, proapoptotic, antiangiogenic,
and immunomodulatory effects. A systematic meta-analysis of 26 randomized controlled
trials, including almost 1.5 million patients and 4,298 cases of HCC, showed that the use of statins
was associated with a 37% reduction in HCC incidence after adjusting for potential confounders
(67). Although no definite recommendations can be given, diabetic patients at high risk for
development of HCC should preferentially be treated with metformin if clinically appropriate,
as opposed to insulin or insulin secretagogues. The use of statins should be favored in subjects
with NAFLD, not only to decrease HCC risk but also in consideration of their increased risk of
cardiovascular events.

TREATMENT OF HEPATOCELLULAR CARCINOMA
The therapeutic options for NAFLD-related HCC are the same as those for any patient with
liver disease (LT, resection, radiofrequency ablation, chemoembolization, sorafenib) (68), but
late diagnosis, older age, and concurrent metabolic or vascular disease restrict the options for
potentially curative treatments. In the study by Dyson et al. (30), the majority of 136 NAFLDrelated
HCC patients received only supportive care or transarterial chemoembolization (TACE).
Because of the lower prevalence of cirrhosis, resection was more frequent, although LT was
performed less often (30). In another study from Germany (69) comparing 45 NASH-related
HCC and 1,074 non-NASH-related HCC cases, resection or LT was performed in only 17.8%
and 4.4% of patients with NASH-related HCC, despite preserved liver function. In both studies,
a larger tumor size and a higher rate of multifocality at the time of diagnosis were the reasons for
the exclusion of LT in NASH-relatedHCC patients; sorafenib was more frequently administered
as primary treatment.
Nevertheless, NASH is currently the most rapidly growing indication for LT in patients with
HCC. A recent study analyzed the burden ofNASHamong 10,061 patients who underwentLTfor
primary HCC (70). The proportion of HCV-related HCC increased steadily from 2002 to 2012,
and HCV remained the leading etiology of HCC (43.4% in 2002 and 49.9% in 2012). However,
NASH-relatedHCC rose from 8.3% in 2002 to 13.5% in 2012, thus becoming the second leading
etiology of HCC treated by LT. Importantly, the number of patients undergoing LT for NASHrelated HCC increased by nearly fourfold, compared to a twofold increase in LT for those with HCV-related HCC. The higher rate of comorbidities in NASH patients may explain the higher
mortality among patients on the waiting list for LT, particularly for those with BMI >40 kg/m2.
In patients with very high BMI, especially morbid obesity, LT might be contraindicated, and
in some centers physical exercise and treatment of obesity are recommended as preparation for
LT. Bariatric surgery might be difficult or impossible in patients with end-stage liver disease, but
preliminary results suggest that combined LT along with sleeve gastrectomy might be considered
in appropriate patients with persistent obesity and MetS prior to LT. A recent meta-analysis
concluded that five-year survival inNAFLDdoes not differ from non-NAFLD because the greater





In consideration of the spread of obesity and NAFLD in the general population, the growing
incidence of HCC linked to these novel risk factors can become a serious challenge for public
health, with high costs for surveillance and treatment, including LT. Importantly, a considerable
number of NAFLD-associated HCC cases develop in noncirrhotic livers, particularly in
patients with multiple metabolic risk factors. Delay in diagnosis and the presence of relevant
comorbidities often limit the possibility of therapeutic intervention. Although weight loss can
generally ameliorate obesity-induced complications, the capability to prevent the development of
HCC or halt its progression is unknown. Many other questions remain to be answered, including
carcinogenesis in noncirrhotic livers and the best strategy for targeting high-risk subjects in the
general population. A better understanding of the molecular events leading from obesity to NASH
and HCC will allow the discovery of new targets for therapeutic and preventive intervention. In
the meanwhile, the best and probably sole effective intervention to address this growing problem
is to hinder the spread of obesity andNAFLD through public awareness and education programs.
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In the setting of NAFLD, low-grade chronic inflammation and IR create a microenvironment suitable for HCC growth. TNFαand IL-6 enhance JNK/NF-κB and JAK/STAT3 pathways while leptin activates PI-3K/Akt signaling, leading to the expression of genes involved in cell proliferation, migration, and survival. Other factors such as SOCS3 and PTEN are downregulated and fail to block molecular HCC-related signaling. High-fat diets and high carbohydrate intake (mainly fructose) can worsen the cytokine pattern and increase hepatic DNL, in turn promoting lipoperoxidation. The intestinal dysbiosis associated with obesity alters the gut microbiome and promotes the release of endotoxins, LPS, and DCA, leading to the activation of HSCs and expression of SASP in the liver. Genetic inheritance contributes to increase the risk of HCC, mainly through the PNPLA3 rs738409 variant. See text for further details.
Abbreviations: Akt, protein kinase B; AMP, adenosine monophosphate; ApoB, apolipoprotein B gene; ChREBP, carbohydrate response element binding protein; DCA, deoxycholic acid; DNL, de novo lipogenesis; F, fructose; FFAs, free fatty acids; G, glucose; HCC, hepatocellular carcinoma; IL-6, interleukin-6; HSC, hepatic stellate cells; IR, insulin resistance; JAK, Janus kinase; JNK, c-Jun N-terminal kinases; LPS, lipopolysaccharides; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa-B kinase beta subunit; NAFLD, nonalcoholic fatty liver disease; PNPLA3, patatin-like phospholipase domain-containing 3 gene; PTEN, phosphatase and tensin homolog; SASP, senescence-associated secretory phenotype; SOCS3, suppressor of cytokine signaling 3; SREBP, sterol-regulatory element binding protein; STAT3, signal transducer and activator of transcription 3; TERT, telomerase reverse transcriptase gene; TG, triglycerides; TNFα, tumor necrosis factor alpha.



